Canaccord raised the firm’s price target on Kenvue (KVUE) to $29 from $24 and keeps a Buy rating on the shares. The firm raised its price target due to a strong cold/flu season as the elevated incidence rates for cough/cold/flu-like illnesses could drive an unplanned replenishment opportunity.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KVUE:
- Kenvue files automatic mixed securities shelf
- Kenvue price target raised to $27 from $24 at Piper Sandler
- Kenvue, Inc.: Balancing Innovation and Market Challenges Justifies Hold Rating
- Kenvue Inc call volume above normal and directionally bullish
- Strategic Initiatives and Innovation Propel Kenvue, Inc. Towards Growth Amidst Challenges
Questions or Comments about the article? Write to editor@tipranks.com